Nutex Health Q3 revenue beats expectations

Reuters
2025.11.19 21:17
portai
I'm PortAI, I can summarize articles.

Nutex Health's Q3 revenue grew 239.9% year-over-year, beating analyst expectations with $267.8 million. The company reported a net income of $55.4 million, reversing a loss from Q3 2024, and regained Nasdaq compliance. Hospital division revenue increased 262.8%. The stock has a median 12-month price target of $220.00, 54.9% above its recent closing price. The current analyst rating is 'buy'.

)

Overview

  • Nutex Health Q3 revenue grows 239.9% yr/yr, beating analyst expectations
  • Net income for Q3 2025 at $55.4 mln, reversing loss from Q3 2024
  • Company regains Nasdaq compliance following timely filing of reports

Outlook

  • Company did not provide specific future guidance

Result Drivers

  • HOSPITAL REVENUE - Hospital division revenue increased 262.8% driven by higher acuity claims and IDR process success
  • ARBITRATION COSTS - Arbitration costs approximated 24-26% of arbitration-related revenue due to underpayment from payors
  • STOCK-BASED COMPENSATION - Stock-based compensation expenses increased due to obligations for under-construction hospitals

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $267.8 $213.81

Revenue mln mln (3

Analysts

)

Analyst Coverage

  • The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 3 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”
  • Wall Street’s median 12-month price target for Nutex Health Inc is $220.00, about 54.9% above its November 18 closing price of $99.20
  • The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 8 three months ago For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.